References
- WHO. Guidelines for the managing advanced HIV disease and rapid initiation of antiretroviral therapy. July 2017. http://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en Accessed April 1, 2019.
- Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017;4:e349–56.
- Prieto P, Podzamczer D. Switching strategies in the recent era of antiretroviral therapy. Expert Rev Clin Pharmacol. 2019;12(3):235–247. Epub 2019 Feb 13.
- Lee FJ, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. PLoS One.2014;9(5):e97482.
- Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. AIDS 2019;33(5):773–791.
- Gupta N, Mittal A, Vinod KS, et al. Is there a need for shifting patients on long term nevirapine based regimens to efavirenz based regimens: a cross-sectional study?. Drug Discov Ther. 2018;12(5):295–298.
- Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2006;22(4):321–329.
- Podzamczer D, Tiraboschi JM, Mallolas J, et al. Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years. Curr HIV Res. 2012 Sep;10(6):513–520.
- Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805–810.
- Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19(9):917–925.
- Podzamczer D, Andrade-Villanueva J, Clotet B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med. 2011;12(6):374–382.
- Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metabol. 2003;88(11):5186–5192.
- Petchkum P, Sungkanuparph S, Kiertiburanakul S, et al. Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial. Open Forum Infect Dis. 2019;6:ofz155.
- Zhou J, Phanupak P, Kiertiburanakul S, Ditangco R, Kamarulzaman A, Pujary S, TREAT Asia HIV Observational Database Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. J Acquir Immune Defic Syndr. 2006;43(4):501–503.
- Marinho AT, Miranda JP, Caixas U, et al. Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. Drug Metab Rev. 2019;3:1–15.
- Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, toleraSingularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicitybility and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17(15):2267–2269.
- Pujari SN, Patel AK, Naik E, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immune Defic Syndr. 2004; 37(5):1566–1569.
- George C, Yesoda A, Jayakumar B, Lal L. A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India. J Clin Pharm Ther. 2009; 34(1):33–40.
- Ayele TA, Worku A, Kebede Y, et al. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies. Syst Rev. 2017;6(1):173.
- Mulisa D, Tesfa M, Mullu Kassa G, Tolossa T. Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study. BMC Infect Dis. 2019 Dec 3;19(1):1024.
- Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Curr HIV Res. 2009;7:526–532.